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Highlights
•

A needles implant was set up in phantom to simulate prostate brachytherapy treatments

•

In vivo dosimetry was performed in the urethral catheter with MOSkin dosimeters

•

Dual-MOSkin detectors resulted to be accurate dosimeters to perform this task
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Abstract
MOSkin detectors were studied to perform real-time in vivo dose measurements in high dose rate
prostate brachytherapy. Measurements were performed inside an urethral catheter in a gel phantom
simulating a real prostate implant. Measured and expected doses were compared and the
discrepancy was found to be within 8.9% and 3.8% for single MOSkin and dual-MOSkin
configurations, respectively. Results show that dual-MOSkin detectors can be profitably adopted in
prostate brachytherapy treatments to perform real-time in vivo dosimetry inside the urethra.
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1. Introduction
1.1 In vivo dosimetry in radiotherapy
The recent developments of more sophisticated radiotherapy and brachytherapy (BT) techniques
call for the improvement of instruments and methodologies employed for the quality control of the
performed treatments. Due to the achievable high conformity of modern BT associated with steep
dose gradients, a careful verification of the accuracy in the delivered dose distributions, as planned
by the Treatment Planning System (TPS) through mathematical models, is gaining importance.
In vivo dosimetry is a reliable method to compare planned and delivered dose distributions,
representing therefore a valid tool to systematically verify treatment accuracy and improve
radiotherapy quality control (Lambert et al 2007, Mijnheer 2008). Particularly advantageous for in
vivo dosimetry are detectors that allow on-line dose reading. These dosimeters provide in fact realtime measurements during treatment, avoiding therapy misadministration and allowing at the same
time intraoperative dose re-planning for treatment error correction.
Current methods for in vivo dosimetry are mainly based on the application of thermoluminescence
detectors (TLDs) (Toye et al 2009) or semiconductor diodes (Waldhäusl et al 2005). TLDs involve
offline process providing the integral dose absorbed during patient treatment and require special
procedures in order to achieve good precision of the results. On the other hand, diodes show rapid
processing time, high sensitivity and immediate reuse, however, they show a high energy
dependence and the delivered dose is therefore not promptly inferred from the diode reading.
Moreover, the major disadvantages of diodes are their relative large sizes, which make them unable
to be held in many catheters placed inside the patient to perform in vivo dosimetry.
New detectors such as fiber optic coupled scintillation dosimeters (Suchowerska et al 2007,
Therriault-Proulx et al 2011) and metal oxide semiconductor field effect transistors (MOSFETs)
(Zilio et al 2006, Fagerstrom et al 2008) have recently been introduced to perform in vivo
dosimetry. In particular, MOSFETs show many advantages, such as good spatial resolution, high
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sensitivity, real time read-out without deterioration of information, negligible radiation field
perturbation owing to their small size and ease of use. In particular, great interest was dedicated to
the application of MOSFETs to BT, because the typical large dose gradients achieved in BT
necessitate a small detector with a reduced active volume for accurate dosimetry. In this work, a
specific type of MOSFET dosimeter called “MOSkin” which has developed by the Centre for
Medical Radiation Physics (CMRP) of the University of Wollongong (Australia) (Qi et al 2007,
Kwan et al 2008, Kwan et al 2009) has been studied.
1.2 High dose rate prostate brachytherapy
High dose rate (HDR) prostate BT allows the delivery of local and high conformal dose directly
into the tumour, minimizing exposure of the surrounding healthy tissues. Due to the large dose
delivered to the target in a single fraction and the dose constraints to be simultaneously satisfied for
organs at risk , it is very important to have as small as possible discrepancy between planned and
delivered dose. The development and application of reliable and accurate methods for monitoring
the dose delivered to critical organs is therefore crucial.
Among these organs at risk, the urethra is most likely susceptible to acute and/or late toxicity
resulting from the treatment (i.e. urethritis, stenosis), as it is inside the target volume (figure 1a).
However, its localization for treatment planning purposes is particularly difficult due to images
artefacts generated by the presence of source catheters, especially if transrectal ultrasound imaging
is performed. Moreover, source catheters are themselves difficult to be accurately localized on the
same images and therefore calculated dose distributions are susceptible to inaccuracies (figure 1b).
The real time dosimetry in the urethra is therefore very important and will be supplementary to
reinforce existing QA programs.
Studies aimed at characterizing the dosimetric properties of MOSkin dosimeters have already
demonstrated that they are promising instruments for performing in vivo dosimetry during HDR BT
treatments (Qi et al 2007, Kwan et al 2008, Qi et al 2012). Measurements finalized to detect the
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accuracy of the dosimeters and the change in sensitivity as a function of depth and angle of
incidence of the radiation, have already shown good agreement between MOSkin response and dose
calculated by the TPS (Hardcastle et al 2010). Aim of this work was to study and develop the
applicability of the MOSkin dosimeters for urethral dose measurement in prostate HDR BT.

2. Materials and Method

2.1 MOSkin dosimetry system
The design of this particular type of MOSFET is optimized to measure dose in steep dose gradients.
Different from other commercial MOSFETs, MOSkin die is embedded in

a thin kapton layer and

hermetically sealed with water-equivalent flexible carrier of reproducible thickness and avoid traditional
wire bonding with high –Z wires . The sensitive volume, defined by the volume of the gate oxide, is 4.8 x 106

mm3. MOSkin detectors can be adopted alone or coupled in a face-to-face arrangement. This face-to-face

dual-MOSkin arrangement is referred to in this text as the “dual-MOSkin”. The dual-MOSkin, proposed and
developed at CMRP, allows for angular-independent measurements as it compensates the naturally
asymmetrical structure of the MOSFET chip relative to the beam direction (Hardcastle et al 2010). The
dosimetry system adopted with MOSkin detectors includes a microprocessor based reader which is connected
to a laptop provided with a dedicated software (“MosPlot”). The computer data acquisition system measures
periodically the instantaneous voltage signal with a user defined frequency. The “MosPlot” software allows
for the online graphical representation of the change in the threshold voltage (proportional to accumulated
dose) or increments in the threshold voltage for consecutive readouts (proportional to dose rate).

2.2 Nucletron Microselectron-HDR Brachytherapy facility
BT irradiations were performed using a Microselectron-HDR (Nucletron,Veenendaal, the
Netherlands) high dose rate remote afterloading device. The facility is provided with a
-5-

192

Ir

radioactive source which has an active length of 3.6mm and a diameter of 0.65mm. The source is
sealed inside a capsule that is welded to one end of a flexible steel cable and the treatment unit
moves it to the required dwell positions.
Experimental determinations of absolute dose rates to water from high-energy sources should have
direct traceability of the source Air Kerma Strength Sk to a primary or secondary standard
dosimetry laboratory (PSDL OR SSDL) (Perez-Calatayud et al, 2012). In our case, the Sk was
certificated by the vendor with 5% (k=3) uncertainty using a calibration instrument traceable to the
standard of the PSDL Physikalisch-Technische Bundesanstalt (PTB, Braunschweig, Germany).
Moreover, the certified Sk was independently verified at our hospital before its clinical application,
by the qualified medical physicist using a calibrated well-type chamber traceable to a PSDL. The
well-type chamber has a vented sensitive volume of 200cc (Source Dosimetry System. Nucletron,
Veenendaal, the Netherlands) (Nath et al 1997) and has proven to be a fast and precise measuring
instrument (Azhari et al, 2012). The delivered dose distribution is calculated by TPS Oncentra
Brachytherapy (Nucletron, Veenendaal, the Netherlands) and is based on the recommendations of
the American Association of Physics in Medicine (AAPM) TG-43 report (Rivard et al 2004)..

2.3 MOSkin and dual-MOSkin calibration and response at increasing source-detector distance
Each single MOSkin and dual-MOSkin was calibrated in a water phantom at a distance of 38mm
from the

192

Ir HDR source. A suitable support for accurate and reproducible detector and source

positioning was developed to perform this task (figure 2) and the experimental set-up was
accurately defined by means of CT imaging (slice thickness: 0.8mm) and catheter digital
reconstruction. Five irradiations were performed for defined source dwell times and the mean
values of MOSkin threshold voltage changes were obtained. Each detector was finally calibrated
considering the correspondent dose value calculated by means of the TPS in the same position
where the active component of the dosimeter was placed. To investigate MOSkin sensitivity
variation vs source–detector distance due to changing of the photon energy spectrum from the Ir-6-

192 source, distance dependent correction factor (CF) was evaluated for measurements performed
at locations other than the calibration position, ranging from 7mm to 46mm and from 11mm to
44mm along the source transverse axis in the water phantom for MOSkin and dual-MOSkin
dosimeters, respectively. In each one of these locations, measurements were repeated five times.

2.4 In phantom simulations of prostate treatments
With the aim of performing dose measurements with implants and conditions simulating typical
prostate treatments, a suitable gel phantom was realized. The phantom has a cylindrical shape with
length of 14.5 cm, and a diameter of 17.6 cm. The urethral catheter and 14 interstitial needles were
placed inside the gel phantom through a real prostate treatment template. Single or dual-MOSkins
were inserted in the urethral catheter. CT images (0.8mm slice thickness) were acquired in order to
precisely localize needles and the urethral catheter containing the dosimeter. In the treatment
planning phase, the presence of a prostate was virtually created by drawing it on the CT images
around the needles implant. The urethral catheter was as well segmented and different treatments
were planned by prescribing the dose to the outlined prostate. The expected doses to the dosimeters
were evaluated from the TPS. In fact, MOSkin detectors could be accurately recognized on CT
images’ reconstructions as small radiopaque spots inside the urethral catheter (figure 3). During
irradiation, the plastic needles were connected to the BT afterloader system thought transfer tubes
and MOSkins were connected to the CMRP computerized reader for the on-line acquisition of dose
measurements (figure 4).
A series of measurements of the same irradiation set-up was performed with different dose
prescriptions according to the developed treatment plans. The total urethral dose measured with the
single or dual-MOSkin detector was compared to the expected dose in the same point. Moreover,
the contributions to the total dose given by the source moving in each single needle were calculated
separately and compared to the measured ones.
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3. Results and discussion
Single MOSkin and dual-MOSkin detectors calibration factors obtained in the water phantom on the
Ir-192 source resulted 0.38 cGy/mV and 0.30 cGy/mV, respectively. Distance dependent CFs at
different source-detector distances for single MOSkin data were in accordance with those reported
in Qi et al (2012); the significant increase of CF at decreasing source-detector distance was
observed. In contrary to single MOSkins, CFs for dual-MOSkins showed a relatively flat response
with changing the Ir-192 source-detector distance (figure 5). It is important to note that reference
dose data to perform dosimeter calibration were not obtained experimentally by a further dosimeter,
but were those resulting from the TPS and cross-checked with a home made software based on the
AAPM TG-43 algorithm (Rivard et al, 2004). The chosen Λ, G(r,θ), F(r,θ) and g(r) factors were
those tabulated in Daskalov et al (1998), which were obtained by means of a Monte Carlo (MC)
photon transport code knowing the characteristics of the Nucletron model mHDR-v2 source.
Consensus on these data has been widely achieved and the resulting AAPM TG-43 algorithm
calculations, when performed in reference conditions of unbounded water medium, are highly
accurate (Daskalov et al, 1998). In fact, the role of experimental dosimetry for high-energy BT may
be more limited than MC-based dosimetry. With high energy BT sources, range and spatial
resolution limitations are for instance not of concern for MC methods (Perez-Calatayud et al, 2012).
Comparison of total dose measured in the gel phantom for the BT prostate implant with the singleMOSkin detector and the expected doses in the same points are reported in Table 1. Measurements
were repeated for three different treatment plans with different dose prescriptions. The maximum
discrepancy between expected and measured dose was found to be 8.9%. Figure 6a shows measured
and calculated contribution to the total dose resulting by the source dwelling in each of the 14
needles adopted to simulate the prostate implant, for one of the three different sets of measures.
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Excluding needles that give a low contribution to the cumulative dose (<20cGy), single point dose
differences resulted less than 15%.
Comparison of total doses measured with the dual-MOSkin detector and the expected doses in the
same point is reported in Table 2 for three different measurement sessions. It was found that
discrepancy was within 3.8%. Figure 6b shows measured and calculated contribution to the total
dose resulting by the source moving in each of the 14 needles adopted to simulate the prostate
implant, for one of the measured treatment sessions. Excluding needles that give a low contribution
to the cumulative dose (<20cGy), single dose differences resulted in general smaller then those
resulting with a single MOSkin readings (i.e. max 8%).
Results obtained for both single MOSkin and dual-MOSkin dosimeters are summarized in the plot
in figure 7. Dual-MOSkin configuration provides greater accuracy than a single MOSkin detector as
angular isotropy and depth dose are greatly improved. Single MOSkin accuracy could be partially
increased by applying measured CFs at changing source-detector distances and further CFs that take
into account its orientation with respect to the source position. However, CFs are almost impossible
to be correctly adopted whenever MOSkins are used as real-time in vivo dosimeters because sourcedetector distances and MOSkin orientation cannot be easily quantified and taken into account.

4. Conclusions
In prostate HDR BT treatments, a very high dose over a few fractions is delivered. In such
conditions, real time dosimetry is most valuable in detecting a dose error at the onset of treatment,
providing the capability of immediate corrections. Measurements performed in a phantom
simulating a typical prostate implant with MOSkin detectors placed within the urethral catheter have
shown that they allow evaluation of the actual dose to the urethra during a treatment fraction.
Through an online comparison between the measured and expected dose, the dosimetry system
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might offer a further security to detect and prevent significant errors in the clinical routine of HDR
BT prostate treatments.
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Figure captions
Figure 1: a) 3D graphical representation of an HDR brachytherapy plan of the prostate (dark red).
Urethra, rectum and bladder are represented in yellow, green and blue, respectively. Source
catheters are drawn as green lines, source dwell positions are represented by red spheres and
resulting dose distribution (95% isodose) is given in light blue; b) transversal prostate image with
the resulting dose distribution. Characteristic hot spots are present around some of the implanted
needles.

Figure 2: Support to be placed in a water phantom which was developed for dosimeters calibration.
Source catheter can be placed at different distances from the dosimeter.

Figure 3: a) sagittal CT reconstruction and b) transversal CT image including the urethral catheter.
MOSkin dosimeter is clearly recognizable as a radiopaque spot inside the catheter.

Figure 4: Experimental set-up used for in phantom measurements.

Figure 5: Correction factors evaluated at different source-detector distances for single- (white
circles) and dual-MOSkin (gray diamonds) detectors. Plotted error bars are given by the standard
deviation of the measurements and result in the values of 0.025, 0.018, 0.018, 0.019, 0.020, 0.019
and of 0.046, 0.042, 0.043, 0.048, 0.034, 0.032 for single- and dual-MOSkin, respectively.

Figure 6: Measured and expected doses given by the source moving in each of the 14 needles for a)
MOSkin and b) dual-MOSkin detectors.

Figure 7: Comparison between single MOSkin and dual-MOSkin in terms of measured mean dose
differences between expected and measured values, standard errors and standard deviations.
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Tables
Table 1: Total urethral dose measured with a single-MOSkin dosimeter for three different treatments.

Total urethral dose
Measured Dose

Calculated Dose

Dose difference

(cGy)

(cGy)

(%)

1

727.2

798.1

-8.9

2

809.2

828.1

-2.0

3

732.0

799.0

-8.0

Table 2: Total urethral dose measured with a dual-MOSkin dosimeter for three sessions of the same
treatment.

Total urethral dose
Measured Dose

Calculated Dose

Dose difference

(cGy)

(cGy)

(%)

1

1139.5

1148.5

-0.8

2

1126.7

1148.5

-1.9

3

1104.3

1148.5

-3.8
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